A drug has shown promising potential to tackle the debilitating movement side effects of medication used to treat Parkinson’s disease, a study has suggested.
Researchers looked at the effects of the drug NLX-112 on dyskinesia – involuntary movements – which is a common side effect in Parkinson’s sufferers who take levodopa-based medication for several years, Parkinson’s UK, which funded the study, said.
With 145,000 people living with Parkinson’s in the UK, we are desperately in need of a breakthrough treatment and we’re committed to delivering one by 2024.
Scientists from US biotech company Neurolixis tested Marmoset monkeys with Parkinson-like symptoms who had developed dyskinesia in response to levodopa treatment in a one-year study.
The results, published online in the journal Neuropharmacology, showed NLX-112 to successfully reduce the involuntary movement without reducing the effect of the levodopa, which other similar drugs do, Parkinsons UK said.
It is hoped the drug can be moved into clinical trials with humans as it has already been tested on diabetes patients to treat pain and was found to be well-tolerated and safe, the charity said.
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
